DGAP-Adhoc: Biotest AG: Dr. Bernhard Ehmer to become new CEO of Biotest AG

        Print
| Source: EQS Group AG
Biotest AG  / Key word(s): Change of Personnel

09.07.2014 18:12

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

/
Ad-hoc RELEASE
Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Dr. Bernhard Ehmer to become new CEO of Biotest AG

Dreieich, 9 July 2014 - The Supervisory Board of Biotest AG, in its meeting
today, has appointed Dr. Bernhard Ehmer (59) as member of the Executive
Board effective November 1st, 2014. As of January 1st, 2015, Ehmer will
take over the role as CEO from Prof. Dr. Gregor Schulz (64) whose
appointment will then end after twelve years due to reaching the age limit.

Bernhard Ehmer got a PhD in Medicine and was resident in internal medicine
at a teaching hospital of the University of Heidelberg before he started
his career in the pharmaceutical industry first with Boehringer Mannheim,
then with Merck KGaA. Later he was CEO of Fresenius Biotech GmbH before he
joined Imclone Systems Corp. In his last position as CEO & President of
Imclone Systems Corp. his focus has been the successful clinical
development and market preparation of biologic pharmaceuticals. Finally he
successfully integrated most of the key functions of Imclone Systems  into
the organization of Eli Lilly, the parent company of Imclone Systems.

Besides Dr. Bernhard Ehmer as CEO, Dr. Michael Ramroth (CFO) and Dr. Georg
Floß, (COO) will continue to be members of the Executive Board of Biotest
AG.

Biotest Aktiengesellschaft
The Executive Management Board

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.de

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of rheumatoid arthritis and cancer of plasma cells, which are
produced by recombinant technologies. Biotest has more than 2.000 employees
worldwide. The preference shares of Biotest AG are listed in the SDAX on
the Frankfurt stock exchange.

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart

 


09.07.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Biotest AG
              Landsteinerstraße 5
              63303 Dreieich
              Germany
Phone:        0 61 03 - 8 01-0
Fax:          0 61 03 - 8 01-150
E-mail:       investor_relations@biotest.de
Internet:     http://www.biotest.de
ISIN:         DE0005227235, DE0005227201
WKN:          522723, 522720
Indices:      SDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------